Absci highlights progress, updates across proprietary pipeline

Absci (ABSI) Corporation announced updates and progress across its internal pipeline of proprietary Drug Creation programs, as well as new breakthroughs demonstrated by Absci’s AI Integrated Drug Creation platform. ABS-201: ABS-201 has potential to offer a safe option as compared to current standard of care, Anticipate initiation of Phase 1 clinical trial in 1H 2026. ABS-101: Anticipate initiation of Phase 1 clinical trial in 1H 2025; ABS-301: For this program, Absci has optimized an antibody lead with high affinity and potency, and anticipates selecting a drug candidate in 1H 2025. ABS-501: Anticipate selection of a drug candidate in 2025, and multiple paths for therapeutic development of this program are under consideration.